纖維肌痛治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球纖維肌痛治療市場規模達23億美元，預計2034年將以4.2%的複合年成長率成長，達到34億美元。這得歸功於對纖維肌痛複雜病理生理機制（包括神經化學失衡和中樞敏化）的深入了解。定量感覺測試等診斷方法的進步以及慢性疼痛症候群生物標記的開發，提高了早期診斷的準確性。功能性磁振造影和蛋白質體學分析等技術的整合有助於識別特定的疼痛路徑並制定個人化治療策略，從而促進市場成長。

此外，人工智慧 (AI) 平台和數位健康技術的結合增強了症狀追蹤和管理，從而實現了更個人化的護理方案。神經調節和生物回饋等非侵入性治療的興起，顯示整體治療框架的接受度日益提高。製藥公司、學術機構和臨床醫生之間的跨產業合作促進了先進療法的發展，改變了治療方法和療效的進程。市場涵蓋旨在控制慢性疼痛、疲勞和纖維肌痛相關症狀的藥物和非藥物治療，包括鎮痛藥和抗憂鬱藥等藥物以及替代療法。

由於患者對疼痛、疲勞及其後續症狀管理的期望不斷提高，2024年藥物市場收入達到17億美元。對藥物治療方法的需求不斷成長，這也解釋了藥物市場為何佔據主導地位。主要藥物類別包括抗憂鬱藥、抗驚厥藥和鎮痛藥，這些藥物有助於患者享受更高品質的生活。新藥及其配方改良的上市，以及現有藥物上市許可的增加，例如普瑞巴林，它是首批獲得FDA批准的纖維肌痛治療藥物之一。

根據性別，纖維肌痛治療市場分為男性和女性兩部分。 2024年，女性市場佔據了80.5%的顯著市場。由於該疾病對女性的影響尤其嚴重，因此女性市場佔有一定佔有率。美國國家生物技術資訊中心 (NCBI) 報告稱，纖維肌痛症候群在女性中發病率較高，佔病例總數的80%-96%。這些差異可能是由於荷爾蒙因素、更強烈的疼痛感以及神經系統功能的差異所致。

美國纖維肌痛治療市場規模在2024年達到9.072億美元，得益於其優質的醫療體系、高發生率和龐大的製藥產業。 FDA核准的度洛西汀、米那普崙和普瑞巴林等藥物佔據處方藥市場的主導地位。此外，由於相關宣傳項目和醫療保險覆蓋範圍的擴大，患者尋求治療的動機也進一步提升。新興趨勢包括遠距醫療診斷以及更個人化的醫療方法。新療法的臨床研究涵蓋了非藥物療法，例如認知行為療法和生活方式改變。

全球纖維肌痛治療產業的主要參與者包括雅培實驗室、艾伯維、Amneal Pharmaceuticals、阿斯特捷利康、科羅拉多纖維肌痛中心、禮來公司、魯賓製藥、梅奧診所、諾華、輝瑞、太陽製藥、梯瓦製藥、綜合醫院集團、德克薩斯大學奧斯汀分校健康中心、Viatris 和 Zydus Lifesciences。為了鞏固市場地位，纖維肌痛治療領域的公司正透過大力投資研發來強調創新。這包括改進藥物配方、最佳化給藥方案和改進給藥技術，以提高患者依從性和治療效果。許多領先公司也與學術機構和研究組織建立策略聯盟，以加速下一代療法的發現和商業化。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 全球纖維肌痛盛行率不斷上升
    • 提高對纖維肌痛診斷和治療方案的認知
    • 針對疼痛管理的藥物療法的進展
  • 產業陷阱與挑戰
    • 晚期纖維肌痛治療費用高
    • 專門針對纖維肌痛症的有效藥物供應有限
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供給側影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按治療類型，2021-2034

• 主要趨勢
• 藥物
  • 抗憂鬱藥
  • 抗驚厥藥
  • 止痛藥
  • 肌肉鬆弛劑
  • 其他藥物
• 治療
  • 物理治療
  • 職能治療
  • 其他療法

第6章：市場估計與預測：依性別，2021-2034

• 主要趨勢
• 男性
• 女性

第7章：市場估計與預測：依最終用途，2021-2034

• 主要趨勢
• 醫院
• 專科診所
• 其他最終用途

第8章：市場估計與預測：按地區，2021-2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Abbott Laboratories
• AbbVie
• Amneal Pharmaceuticals
• AstraZeneca
• Colorado Fibromyalgia Center
• Eli Lilly and Company
• Lupin
• Mayo Clinic
• Novartis
• Pfizer
• Sun Pharmaceutical
• Teva Pharmaceutical
• The General Hospital Corporation
• UT Health Austin
• Viatris
• Zydus Lifesciences

The Global Fibromyalgia Treatment Market was valued at USD 2.3 billion in 2024 and is estimated to grow at a CAGR of 4.2% to reach USD 3.4 billion by 2034, driven by a deeper understanding of fibromyalgia's complex pathophysiology, including neurochemical imbalances and central sensitization. Advances in diagnostic methods, such as quantitative sensory testing and the development of biomarkers for chronic pain syndromes, have improved early and accurate diagnosis. Integrating technology, including functional MRI and proteomic analysis, helps in identifying specific pain pathways and tailoring treatment strategies, thereby boosting market growth.

Additionally, incorporating artificial intelligence (AI)-powered platforms and digital health technologies has enhanced symptom tracking and management, enabling more personalized care approaches. The shift towards non-invasive treatments, such as neuromodulation and biofeedback, indicates a growing acceptance of holistic frameworks. Cross-industry collaboration among pharmaceutical companies, academic institutions, and clinical practitioners has catalyzed the development of advanced therapeutics, changing the course of treatment approaches and outcomes. The market encompasses pharmaceutical and non-pharmacological treatments aimed at managing chronic pain, fatigue, and associated symptoms of fibromyalgia, including medications like analgesics and antidepressants, as well as alternative therapies.

The medication segment generated USD 1.7 billion in 2024 due to increased patient expectations regarding pain, fatigue, and subsequent symptom management. Demand is rising for pharmacological approaches, which explains why the medication segment dominates the market. Key drug classes include antidepressants, anticonvulsants, and analgesic drugs that help patients enjoy a better quality of life. The growth in this segment is supported by the launch of new drugs and their reformulations, along with increased marketing authorizations of existing ones, such as pregabalin, one of the first FDA-approved drugs specifically for fibromyalgia.

Based on gender, the fibromyalgia treatment market is divided into male and female segments. The female segment accounted for a significant market share of 80.5% in 2024. The female segment represents a market share, as the condition disproportionately affects women. As reported by the National Center for Biotechnology Information (NCBI), fibromyalgia syndrome has a high female predominance, comprising 80%-96% of cases. These differences have been explained based on hormonal factors, greater pain perception, and variations in the functions of the nervous system.

U.S. Fibromyalgia Treatment Market was valued at USD 907.2 million in 2024 due to its quality healthcare system, high disease prevalence, and extensive pharmaceutical industry. FDA-approved drugs such as duloxetine, milnacipran, and pregabalin dominate the prescription landscape. Patients are further motivated to seek treatment due to awareness programs and insurance coverage. Emerging trends include telemedicine for diagnosis and a shift toward a more personalized approach to medicine. Clinical research for new therapy approaches includes non-pharmaceutical options such as cognitive behavioral therapy and lifestyle changes.

Major players operating in the Global Fibromyalgia Treatment Industry include Abbott Laboratories, AbbVie, Amneal Pharmaceuticals, AstraZeneca, Colorado Fibromyalgia Center, Eli Lilly and Company, Lupin, Mayo Clinic, Novartis, Pfizer, Sun Pharmaceutical, Teva Pharmaceutical, The General Hospital Corporation, UT Health Austin, Viatris, and Zydus Lifesciences. To strengthen their market foothold, companies in the fibromyalgia treatment sector are emphasizing innovation through robust investments in research and development. This includes advancing drug formulations, optimizing dosage regimens, and improving delivery technologies to increase patient adherence and therapeutic effectiveness. Many leading firms are also forming strategic alliances with academic institutions and research organizations to accelerate the discovery and commercialization of next-generation treatments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of fibromyalgia globally
    • 3.2.1.2 Rising awareness about fibromyalgia diagnosis and treatment options
    • 3.2.1.3 Advances in pharmaceutical therapies targeting pain management
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced fibromyalgia treatments
    • 3.2.2.2 Limited availability of effective medications specifically approved for fibromyalgia
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Antidepressants
  • 5.2.2 Anticonvulsants
  • 5.2.3 Analgesics
  • 5.2.4 Muscle relaxants
  • 5.2.5 Other medications
• 5.3 Therapy
  • 5.3.1 Physical therapy
  • 5.3.2 Occupational therapy
  • 5.3.3 Other therapies

Chapter 6 Market Estimates and Forecast, By Gender, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AbbVie
• 9.3 Amneal Pharmaceuticals
• 9.4 AstraZeneca
• 9.5 Colorado Fibromyalgia Center
• 9.6 Eli Lilly and Company
• 9.7 Lupin
• 9.8 Mayo Clinic
• 9.9 Novartis
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical
• 9.12 Teva Pharmaceutical
• 9.13 The General Hospital Corporation
• 9.14 UT Health Austin
• 9.15 Viatris
• 9.16 Zydus Lifesciences